Search for:

Skip to content

Main Navigation

About
Science
Patients
Careers
Investors
Contact

Publications

May 13, 2026

Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial

General Telitacicept, IgA Nephropathy

Presented by: New England Journal of Medicine

About
Science

Patients
Careers

Investors
Contact

© 2026 Vor Bio | Telitacicept is an investigational drug. It has not been approved by the U.S. Food and Drug Administration (FDA). The safety and efficacy of telitacicept have not been established.

Privacy Policy
Terms of Use

Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.